Sage Journals: Discover world-class research

Abstract

Considering the urgency of addressing grand challenges that affect human health and achieving the ambitious health targets set by the United Nations’ Sustainable Development Goals (SDGs), the role of business in improving health has become critical. Yet, our systematic review of the business–health literature reveals that business research focuses primarily on occupational health and safety, health care organizations, and health regulations. To embrace the health externalities generated by business activities, we propose that future research should investigate the conditions under which business (a) articulates and participates in health challenges, (b) engages in multilevel actions toward tackling health challenges, and (c) improves health outcomes and its impact on the health of external stakeholders, including customers and local communities. We also urge business scholars to engage with the public health research community to increase impact.

Keywords

health corporate social responsibility grand challenges stakeholders Sustainable Development Goals

Get full access to this article

View all access options for this article.

References

Adams

(2005). Fast food, obesity, and tort reform: An examination of industry responsibility for public health. Business and Society Review, 110, 297–320.

Anaf

Baum

F. E.

Fisher

Harris

Friel

(2017). Assessing the health impact of transnational corporations: A case study on McDonald’s Australia. Globalization and Health, 13, Article 7.

Angeli

Jaiswal

A. K.

(2016). Business model innovation for inclusive health care delivery at the bottom of the pyramid. Organization & Environment, 29, 486–507.

Anker

Sandøe

Kamin

Kappel

(2011). Health branding ethics. Journal of Business Ethics, 104, 33–45.

Arnold

P. J.

Reeves

T. C.

(2006). International trade and health policy: Implications of the GATS for US healthcare reform. Journal of Business Ethics, 63, 313–332.

Aronson

J. K.

(2006). Rare diseases and orphan drugs. British Journal of Clinical Pharmacology, 61, 243–245.

Atasoy

Chen

Ganju

(2018). The spillover effects of health IT investments on regional healthcare costs. Management Science, 64, 2515–2534.

Balotsky

(2009). Where strategy and ethics converge: Pharmaceutical industry pricing policy for Medicare Part D beneficiaries. Journal of Business Ethics, 84, 75–88.

Bapuji

(2015). Individuals, interactions and institutions: How economic inequality affects organizations. Human Relations, 68, 1059–1083.

10.

Bapuji

Beamish

P. W.

(2019). Impacting practice through IB scholarship: Toy recalls and the product safety crisis. Journal of International Business Studies, 50, 1636–1643.

11.

Barnett

M. L.

Henriques

Husted

B. W.

(2020). Beyond good intentions: Designing CSR initiatives for greater social impact. Journal of Management, 46, 937–964.

12.

Barney

Felin

(2013). What are microfoundations? Academy of Management Perspectives, 27, 138–155.

13.

Baum

F. E.

Sanders

D. M.

Fisher

Anaf

Freudenberg

Friel

Labonté

London

Monteiro

Scott-Samuel

Sen

(2016). Assessing the health impact of transnational corporations: Its importance and a framework. Globalization and Health, 12, Article 27.

14.

Beaver

(1999). Fast-food invades the schools. Business and Society Review, 104, 191–197.

15.

Beets

S. D.

(2019). Business ethics in the broiler industry. Business and Society Review, 124, 239–260.

16.

Bekefi

(2006). Business as a partner in tackling micronutrient deficiency: Lessons in multisector partnership (Corporate Social Responsibility Initiative Report No. 7). John F. Kennedy School of Government, Harvard University.

17.

Berntson

G. G.

Sarter

Cacioppo

J. T.

(1998). Anxiety and cardiovascular reactivity: The basal forebrain cholinergic link. Behavioural Brain Research, 94, 225–248.

18.

Black

R. E.

Allen

L. H.

Bhutta

Z. A.

Caulfield

L. E.

de Onis

Ezzati

Mathers

Rivera

(2008). Maternal and child undernutrition: Global and regional exposures and health consequences. The Lancet, 371(9608), 243–260.

19.

Blair

J. D.

Boal

K. B.

(1991). Strategy formation processes in health care organizations: A context-specific examination of context-free strategy issues. Journal of Management, 17, 305–344.

20.

Blume

(2006). Anti-vaccination movements and their interpretations. Social Science & Medicine, 62, 628–642.

21.

Bluthenthal

R. N.

Palar

Mendel

Kanouse

D. E.

Corbin

D. E.

Derose

K. P.

(2012). Attitudes and beliefs related to HIV/AIDS in urban religious congregations: Barriers and opportunities for HIV-related interventions. Social Science & Medicine, 74, 1520–1527.

22.

Boehm

(2009). Involvement of businesses in the community at times of peace and of war on the home front. Business and Society Review, 114, 85–116.

23.

Boiral

Heras-Saizarbitoria

(2017). Managing biodiversity through stakeholder involvement: Why, who, and for what initiatives? Journal of Business Ethics, 140, 403–421.

24.

Bouncken

R. B.

Qiu

Sinkovics

Kürsten

(2021). Qualitative research: Extending the range with flexible pattern matching. Review of Managerial Science, 15, 251–273.

25.

Braveman

Egerter

Williams

D. R.

(2011). The social determinants of health: Coming of age. Annual Review of Public Health, 32, 381–398.

26.

Braveman

Gottlieb

(2014). The social determinants of health: It’s time to consider the causes of the causes. Public Health Reports, 129(1_suppl 2), 19–31.

27.

Brown

J. A.

Gianiodis

P. T.

Santoro

M. D.

(2015). Following doctors’ orders: Organizational change as a response to human capital bargaining power. Organization Science, 26, 1284–1300.

28.

BSR. (2016). The healthy business strategy tool. The Healthy Business Coalition. https://healthybusiness.bsr.org/toolkit/strategy-tool

29.

BSR. (2018). The healthy business metrics guide. The Healthy Business Coalition. https://healthybusiness.bsr.org/toolkit/metrics-guide

30.

Cai

Pan

(2012). Doing well while doing bad? CSR in controversial industry sectors. Journal of Business Ethics, 108, 467–480.

31.

Carroll

A. B.

(1979). A three-dimensional conceptual model of corporate performance. Academy of Management Review, 4, 497–505.

32.

Carroll

A. B.

(1991). The pyramid of corporate social responsibility: Toward the moral management of organizational stakeholders. Business Horizons, 34(4), 39–48.

33.

Carroll

A. B.

(1999). Corporate social responsibility: Evolution of a definitional construct. Business & Society, 38, 268–295.

34.

Castro

M. C.

Baeza

Codeço

C. T.

Cucunubá

Z. M.

Dal’Asta

A. P.

Leo

G. A. D.

Dobson

A. P.

Carrasco-Escobar

Lana

R. M.

Lowe

Monteiro

A. M. V.

Pascual

Santos-Vega

(2019). Development, environmental degradation, and disease spread in the Brazilian Amazon. PLOS Biology, 17(11), Article e3000526.

35.

Chaar

B. B.

Lee

(2012). Role of socioeconomic status on consumers’ attitudes towards DTCA of prescription medicines in Australia. Journal of Business Ethics, 105, 447–460.

36.

Chandra

Holt

G. A.

(1999). Pharmaceutical advertisements: How they deceive patients. Journal of Business Ethics, 18, 359–366.

37.

Christian

M. S.

Wallace

J. C.

Bradley

J. C.

Burke

M. J.

(2009). Workplace safety: A meta-analysis of the roles of person and situation factors. Journal of Applied Psychology, 94, 1103–1127.

38.

Clapp

Scrinis

(2017). Big food, nutritionism, and corporate power. Globalizations, 14, 578–595.

39.

Clifford

(1996, July 3). Utility to pay $333 million to settle suit. Los Angeles Times. https://www.latimes.com/archives/la-xpm-1996-07-03-mn-20787-story.html

40.

Cohen

(1960). A coefficient of agreement for nominal scales. Educational and Psychological Measurement, 20, 37–46.

41.

Cooper

(2006). A preview of disruption. Harvard Business Review, 84(5), Article 36.

42.

Cuervo-Cazurra

Doh

J. P.

Giuliani

Montiel

Park

(in press). The United Nations’ Sustainable development goals: Pros and cons for managers of multinationals. AIB Insights.

43.

Culnan

M. J.

(1986). The intellectual development of management information systems, 1972–1982: A co-citation analysis. Management Science, 32, 156–172.

44.

Dahan

Doh

Guay

(2006). The role of multinational corporations in transnational institution building: A policy network perspective. Human Relations, 59, 1571–1600.

45.

Damaraju

N. L.

Makhija

A. K.

(2018). The role of social proximity in professional CEO appointments: Evidence from caste/religion-based hiring of CEOs in India. Strategic Management Journal, 39, 2051–2074.

46.

Danley

J. R.

(2005). Polishing up the Pinto: Legal liability, moral blame, and risk. Business Ethics Quarterly, 15, 205–236.

47.

Danna

Griffin

R. W.

(1999). Health and well-being in the workplace: A review and synthesis of the literature. Journal of Management, 25, 357–384.

48.

Daszak

Cunningham

A. A.

Hyatt

A. D.

(2000). Emerging infectious diseases of wildlife—Threats to biodiversity and human health. Science, 287(5452), 443–449.

49.

de Lacy-Vawdon

Livingstone

. (2020). Defining the commercial determinants of health: A systematic review. BMC Public Health, 20, 1022.

50.

Delmas

M. A.

Burbano

V. C.

(2011). The drivers of greenwashing. California Management Review, 54, 64–87.

51.

Deloitte. (2021, April 16). Organizations are feeling the pain of climate change: Here are five ways it’s affecting their business. Forbes. https://www.forbes.com/sites/deloitte/2021/04/16/organizations-are-feeling-the-pain-of-climate-change-here-are-five-ways-its-affecting-their-business/

52.

Delpo

M. C.

(1999). Tobacco abroad: Legal and ethical implications of marketing dangerous United States products overseas. Business and Society Review, 104, 147–162.

53.

Dembek

Sivasubramaniam

Chmielewski

D. A.

(2020). A systematic review of the bottom/base of the pyramid literature: Cumulative evidence and future directions. Journal of Business Ethics, 165, 365–382.

54.

Derry

Waikar

S. V.

(2008). Frames and filters: Strategic distrust as a legitimation tool in the 50-year battle between public health activists and big tobacco. Business & Society, 47, 102–139.

55.

Dewhirst

Lee

Fong

Ling

(2016). Exporting an inherently harmful product: The marketing of Virginia Slims cigarettes in the United States, Japan, and Korea. Journal of Business Ethics, 139, 161–181.

56.

Diestre

Barber

IV. Santaló

(2020). The Friday effect: Firm lobbying, the timing of drug safety alerts, and drug side effects. Management Science, 66, 3677–3698.

57.

DiMaggio

P. J.

Powell

W. W.

(1983). The iron cage revisited: Institutional isomorphism and collective rationality in organizational fields. American Sociological Review, 48(2), 147–160.

58.

Dimsdale

J. E.

(2008). Psychological stress and cardiovascular disease. Journal of the American College of Cardiology, 51, 1237–1246.

59.

Dorobantu

Kaul

Zelner

(2017). Nonmarket strategy research through the lens of new institutional economics: An integrative review and future directions. Strategic Management Journal, 38, 114–140.

60.

Dunham

Freeman

R. E.

Liedtka

(2006). Enhancing stakeholder practice: A particularized exploration of community. Business Ethics Quarterly, 16, 23–42.

61.

Dutton

J. E.

Duncan

R. B.

(1987). The creation of momentum for change through the process of strategic issue diagnosis. Strategic Management Journal, 8, 279–295.

62.

Elia

Margherita

Petti

(2020). Building responses to sustainable development challenges: A multistakeholder collaboration framework and application to climate change. Business Strategy and the Environment, 29, 2465–2478.

63.

Elmes

M. B.

(2018). Economic inequality, food insecurity, and the erosion of equality of capabilities in the United States. Business & Society, 57, 1045–1074.

64.

Felin

Foss

N. J.

Ployhart

R. E.

(2015). The microfoundations movement in strategy and organization theory. Academy of Management Annals, 9, 575–632.

65.

Festinger

(1954). A theory of social comparison processes. Human Relations, 7(2), 117–140.

66.

Flanagan

Whiteman

(2007). “AIDS is not a business”: A study in global corporate responsibility—securing access to low-cost HIV medications. Journal of Business Ethics, 73, 65–75.

67.

Flasher

Lamboy-Ruiz

M. A.

(2019). Impact of enforcement on healthcare billing fraud: Evidence from the USA. Journal of Business Ethics, 157, 217–229.

68.

Folger

Cropanzano

(1998). Organizational justice and human resource management. SAGE.

69.

Fottler

M. D.

(1987). Health care organizational performance: Present and future research. Journal of Management, 13, 367–391.

70.

Freeman

R. E.

(1984). Strategic management: A stakeholder approach. Pitman.

71.

French

J. L.

(2010). Children’s labor market involvement, household work, and welfare: A Brazilian case study. Journal of Business Ethics, 92, 63–78.

72.

Frenk

Gómez-Dantés

Knaul

F. M.

(2011). Globalization and infectious diseases. Infectious Disease Clinics, 25, 593–599.

73.

Freudenberg

(2014). Lethal but legal: Corporations, consumption, and protecting public health. Oxford University Press.

74.

Ganster

D. C.

Rosen

C. C.

(2013). Work stress and employee health: A multidisciplinary review. Journal of Management, 39, 1085–1122.

75.

Gautier

Bricher

J. L.

(1991). Lead paint: Old coats lead to new suits. Business and Society Review, 79, 10–21.

76.

George

Howard-Grenville

Joshi

Tihanyi

(2016). Understanding and tackling societal grand challenges through management research. Academy of Management Journal, 59, 1880–1895.

77.

Germano

Montiel

(2011). Fast food, childhood obesity and local government regulations: No more fun and games. In Collins

(Ed.), Business ethics: How to design and manage ethical organizations (1st ed., pp. 415–422). Wiley.

78.

Gewertz

N. M.

Amado

(2004). Intellectual property and the pharmaceutical industry: A moral crossroads between health and property. Journal of Business Ethics, 55, 295–308.

79.

Gilmore

A. B.

Savell

Collin

(2011). Public health, corporations and the new responsibility deal: Promoting partnerships with vectors of disease? Journal of Public Health, 33, 2–4.

80.

Glantz

S. A.

(1996). Preventing tobacco use—The youth access trap. American Journal of Public Health, 86(2), 156–158.

81.

Gould

R. V.

(2002). The origins of status hierarchies: A formal theory and empirical test. American Journal of Sociology, 107, 1143–1178.

82.

Grandey

A. A.

Gabriel

A. S.

King

E. B.

(2020). Tackling taboo topics: A review of the three Ms in working women’s lives. Journal of Management, 46, 7–35.

83.

Gusenbauer

Haddaway

N. R.

(2020). Which academic search systems are suitable for systematic reviews or meta-analyses? Evaluating retrieval qualities of Google Scholar, PubMed, and 26 other resources. Research Synthesis Methods, 11(2), 181–217.

84.

Hagerty

M. R.

(2000). Social comparisons of income in one’s community: Evidence from national surveys of income and happiness. Journal of Personality and Social Psychology, 78, 764–771.

85.

Hahn

Figge

Pinkse

Preuss

(2010). Trade-offs in corporate sustainability: You can’t have your cake and eat it. Business Strategy and the Environment, 19, 217–229.

86.

Han

Hyun

S. S.

(2019). Green indoor and outdoor environment as nature-based solution and its role in increasing customer/employee mental health, well-being, and loyalty. Business Strategy and the Environment, 28, 629–641.

87.

Han

Olya

H. G. T.

Untaru

Ispas

Kim

J. J.

Kim

(2020). Impact of airport green atmospherics on mental health value, image, and loyalty among visitors and workers. Business Strategy and the Environment, 29, 1186–1198.

88.

Hannan

M. T.

Freeman

(1977). The population ecology of organizations. American Journal of Sociology, 82, 929–964.

89.

Harvard School of Public Health. (2010, June 22). Press release: Employers took many measures to protect employees and avoid business impact of H1N1 flu outbreak. https://www.hsph.harvard.edu/news/press-releases/businesses-took-measures-to-protect-employees-from-h1n1-flu/

90.

Hegde

Sampat

(2015). Can private money buy public science? Disease group lobbying and federal funding for biomedical research. Management Science, 61, 2281–2298.

91.

Held

Kickbusch

McNally

Piselli

Told

(2019). Gridlock, innovation and resilience in global health governance. Global Policy, 10(2), 161–177.

92.

Hemphill

T. A.

(2010). Extraordinary pricing of orphan drugs: Is it a socially responsible strategy for the U.S. pharmaceutical industry? Journal of Business Ethics, 94, 225–242.

93.

Hemphill

T. A.

(2019). Generic drug competition: The pharmaceutical industry “gaming” controversy. Business and Society Review, 124, 467–477.

94.

Husted

B. W.

(1998). Organizational justice and the management of stakeholder relations. Journal of Business Ethics, 17, 643–651.

95.

Husted

B. W.

Folger

(2004). Fairness and transaction costs: The contribution of organizational justice theory to an integrative model of economic organization. Organization Science, 15, 719–729.

96.

Ibanez

M. R.

Toffel

M. W.

(2020). How scheduling can bias quality assessment: Evidence from food-safety inspections. Management Science, 66, 2396–2416.

97.

Iyer

Singh

(2018). Voluntary product safety certification. Management Science, 64, 695–714.

98.

Jacobson

C. K.

(1994). Investor response to health care cost containment legislation: Is American health policy designed to fail? Academy of Management Journal, 37, 440–452.

99.

Jenkins

J. C.

(1983). Resource mobilization theory and the study of social movements. Annual Review of Sociology, 9, 527–553.

100.

Jiang

Probst

T. M.

(2017). The rich get richer and the poor get poorer: Country- and state-level income inequality moderates the job insecurity-burnout relationship. Journal of Applied Psychology, 102, 672–681.

101.

Johnson

(2015). How I did it . . . SC Johnson’s CEO on doing the right thing, even when it hurts business. Harvard Business Review, 93(4), 33–36.

102.

Johnston

L. M.

Finegood

D. T.

(2015). Cross-sector partnerships and public health: Challenges and opportunities for addressing obesity and noncommunicable diseases through engagement with the private sector. Annual Review of Public Health, 36, 255–271.

103.

Jones

T. M.

(1991). Ethical decision making by individuals in organizations: An issue-contingent model. Academy of Management Review, 16, 366–395.

104.

Jorgenson

A. K.

(2009). Foreign direct investment and the environment, the mitigating influence of institutional and civil society factors, and relationships between industrial pollution and human health: A panel study of less-developed countries. Organization & Environment, 22(2), 135–157.

105.

Karagiannis

Vouros

Skouloudis

Evangelinos

(2019). Sustainability reporting, materiality, and accountability assessment in the airport industry. Business Strategy and the Environment, 28, 1370–1405.

106.

Kickbusch

Allen

Franz

(2016). The commercial determinants of health. The Lancet Global Health, 4(12), e895–e896.

107.

King

G. J.

Chao

Duenyas

(2019). Who benefits when prescription drug manufacturers offer copay coupons? Management Science, 65, 3758–3775.

108.

Kish-Gephart

J. J.

Campbell

J. T.

(2015). You don’t forget your roots: The influence of CEO social class background on strategic risk taking. Academy of Management Journal, 58, 1614–1636.

109.

Kohl

J. P.

Miller

A. N.

Barton

(1990). Levi’s corporate AIDS programme. Long Range Planning, 23(6), 31–34.

110.

Koolhaas

J. M.

Bartolomucci

Buwalda

de Boer

S. F.

Flügge

Korte

S. M.

Meerlo

Murison

Olivier

Palanza

Richter-Levin

Sgoifo

Steimer

Stiedl

van Dijk

Wöhr

Fuchs

(2011). Stress revisited: A critical evaluation of the stress concept. Neuroscience & Biobehavioral Reviews, 35, 1291–1301.

111.

Kraiselburd

Yadav

(2013). Supply chains and global health: An imperative for bringing operations management scholarship into action. Production and Operations Management, 22, 377–381.

112.

Kramer

L. A.

Greek

(2018). Human stakeholders and the use of animals in drug development. Business and Society Review, 123, 3–58.

113.

Kunreuther

Useem

(2009). Learning from catastrophes: Strategies for reaction and response. Pearson.

114.

Kvetnansky

Sabban

E. L.

Palkovits

(2009). Catecholaminergic systems in stress: Structural and molecular genetic approaches. Physiological Reviews, 89, 535–606.

115.

Labonté

Mohindra

Schrecker

(2011). The growing impact of globalization for health and public health practice. Annual Review of Public Health, 32, 263–283.

116.

Landis

J. R.

Koch

G. G.

(1977). The measurement of observer agreement for categorical data. Biometrics, 33, 159–174.

117.

T. T.

Andreadakis

Kumar

Román

R. G.

Tollefsen

Saville

Mayhew

(2020). The COVID-19 vaccine development landscape. Nature Reviews Drug Discovery, 19(5), 305–306.

118.

Lee

H.-H. M.

Van Dolen

Kolk

(2013). On the role of social media in the “responsible” food business: Blogger buzz on health and obesity issues. Journal of Business Ethics, 118, 695–707.

119.

Leisinger

K. M.

(2005). The corporate social responsibility of the pharmaceutical industry: Idealism without illusion and realism without resignation. Business Ethics Quarterly, 15, 577–594.

120.

Leisinger

K. M.

(2009). Corporate responsibilities for access to medicines. Journal of Business Ethics, 85, 3–23.

121.

Levi

Singhvi

Zheng

(2020). Economically motivated adulteration in farming supply chains. Management Science, 66, 209–226.

122.

Luke

R. D.

Begun

J. W.

Pointer

D. D.

(1989). Quasi firms: Strategic interorganizational forms in the health care industry. Academy of Management Review, 14, 9–19.

123.

Lumpkin

G. T.

Bacq

(2019). Civic wealth creation: A new view of stakeholder engagement and societal impact. Academy of Management Perspectives, 33, 383–404.

124.

Lyon

T. P.

Montgomery

A. W.

(2015). The means and end of greenwash. Organization & Environment, 28, 223–249.

125.

MacDonald

Whellams

(2007). Corporate decisions about labelling genetically modified foods. Journal of Business Ethics, 75, 181–189.

126.

Macik-Frey

Quick

J. C.

Nelson

D. L.

(2007). Advances in occupational health: From a stressful beginning to a positive future. Journal of Management, 33, 809–840.

127.

Mair

Martí

Ventresca

M. J.

(2012). Building inclusive markets in rural Bangladesh: How intermediaries work institutional voids. Academy of Management Journal, 55, 819–850.

128.

Maloni

Brown

(2006). Corporate social responsibility in the supply chain: An application in the food industry. Journal of Business Ethics, 68, 35–52.

129.

Management Science. (2021, March 31). Editorial statement. https://pubsonline.informs.org/page/mnsc/editorial-statement

130.

Mayo

A. T.

Myers

C. G.

Sutcliffe

K. M.

(2021). Organizational science and health care. Academy of Management Annals, 15, 537–576.

131.

McCarthy

J. D.

Zald

M. N.

(1977). Resource mobilization and social movements: A partial theory. American Journal of Sociology, 82, 1212–1241.

132.

McKee

Stuckler

(2018). Revisiting the corporate and commercial determinants of health. American Journal of Public Health, 108, 1167–1170.

133.

McLaughlin

(2011). Climate change, adaptation, and vulnerability: Reconceptualizing societal–environment interaction within a socially constructed adaptive landscape. Organization & Environment, 24, 269–291.

134.

Mialon

Vandevijvere

Carriedo-Lutzenkirchen

Bero

Gomes

Petticrew

McKee

Stuckler

Sacks

(2020). Mechanisms for addressing and managing the influence of corporations on public health policy, research and practice: A scoping review. BMJ Open, 10(7), Article e034082.

135.

Millar

J. S.

(2013). The corporate determinants of health: How big business affects our health, and the need for government action! Canadian Journal of Public Health, 104(4), e327–e329.

136.

Mitchell

R. K.

Agle

B. R.

Wood

D. J.

(1997). Toward a theory of stakeholder identification and salience: Defining the principle of who and what really counts. Academy of Management Review, 22, 853–886.

137.

Montiel

(2008). Corporate social responsibility and corporate sustainability: Separate pasts, common futures. Organization & Environment, 21, 245–269.

138.

Montiel

(2020, June 30). Climate change, COVID-19 & systemic racism: Where is the attention now? Business & Society Commentary. https://businessandsociety.org/where-is-the-attention-now/

139.

Montiel

Cuervo-Cazurra

Park

Antolín-López

Husted

B. W.

(2021). Implementing the United Nations’ Sustainable Development Goals in international business. Journal of International Business Studies, 52, 999–1030.

140.

Montiel

Delgado-Ceballos

(2014). Defining and measuring corporate sustainability: Are we there yet? Organization & Environment, 27(2), 113–139.

141.

Moodie

Stuckler

Monteiro

Sheron

Neal

Thamarangsi

Lincoln

Casswell

(2013). Profits and pandemics: Prevention of harmful effects of tobacco, alcohol, and ultra-processed food and drink industries. The Lancet, 381(9867), 670–679.

142.

Moynihan

Doran

Henry

(2008). Disease mongering is now part of the global health debate. PLOS Medicine, 5(5), Article e106.

143.

Moynihan

Heath

Henry

(2002). Selling sickness: The pharmaceutical industry and disease mongering. BMJ, 324(7342), 886–891.

144.

Nill

Laczniak

Thistle

(2019). The use of genetic testing information in the insurance industry: An ethical and societal analysis of public policy options. Journal of Business Ethics, 156, 105–121.

145.

Noggle

Palmer

D. E.

(2005). Radials, rollovers and responsibility: An examination of the Ford-Firestone case. Journal of Business Ethics, 56, 185–203.

146.

Oborn

Barrett

Dawson

(2013). Distributed leadership in policy formulation: A sociomaterial perspective. Organization Studies, 34, 253–276.

147.

Ocasio

(1997). Towards an attention-based view of the firm. Strategic Management Journal, 18(S1), 187–206.

148.

Oddo

A. R.

(2001). Healthcare ethics: A patient-centered decision model. Journal of Business Ethics, 29, 125–134.

149.

Office of the U.S. Surgeon General. (2021). Community health & economic prosperity. https://www.hhs.gov/surgeongeneral/reports-and-publications/community-health-economic-prosperity/index.html

150.

Oliver

(2005). The treadmill of production under NAFTA: Multilateral trade, environmental regulation, and national sovereignty. Organization & Environment, 18, 55–71.

151.

Olson

C. M.

(1999). Nutrition and health outcomes associated with food insecurity and hunger. Journal of Nutrition, 129(2), 521S–524S.

152.

Palazzo

Richter

(2005). CSR business as usual? The case of the tobacco industry. Journal of Business Ethics, 61, 387–401.

153.

Paul

J. A.

Quosigk

MacDonald

(2019). Factors impacting market concentration of not-for-profit hospitals. Journal of Business Ethics, 154, 517–535.

154.

Peterson

M. D.

(1996). Two models for assessing a federal environmental health policy: The case of radon in U.S. homes. Management Science, 42, 1476–1492.

155.

Pfeffer

(2010). Building sustainable organizations: The human factor. Academy of Management Perspectives, 24, 34–45.

156.

Pfeffer

Salancik

G. R.

(1978). The external control of organizations: A resource dependence perspective. Harper and Row.

157.

Pham-Kanter

(2009). Social comparisons and health: Can having richer friends and neighbors make you sick? Social Science & Medicine, 69, 335–344.

158.

Pickett

K. E.

Wilkinson

R. G.

(2015). Income inequality and health: A causal review. Social Science & Medicine, 128, 316–326.

159.

Pisani

Kourula

Kolk

Meijer

(2017). How global is international CSR research? Insights and recommendations from a systematic review. Journal of World Business, 52, 591–614.

160.

Pless

N. M.

Appel

(2012). In pursuit of dignity and social justice: Changing lives through 100% inclusion—How Gram Vikas fosters sustainable rural development. Journal of Business Ethics, 111, 389–411.

161.

Radermacher

Brinkmann

(2011). Insurance for the poor? First thoughts about microinsurance business ethics. Journal of Business Ethics, 103(S1), 63–76.

162.

Ramos-Rodríguez

A.-R.

Ruíz-Navarro

(2004). Changes in the intellectual structure of strategic management research: A bibliometric study of the Strategic Management Journal, 1980–2000. Strategic Management Journal, 25, 981–1004.

163.

Ramus

C. A.

Montiel

(2005). When are corporate environmental policies a form of greenwashing? Business & Society, 44, 377–414.

164.

Rawhouser

Cummings

Newbert

S. L.

(2019). Social impact measurement: Current approaches and future directions for social entrepreneurship research. Entrepreneurship Theory and Practice, 43, 82–115.

165.

Roehrich

J. K.

Lewis

M. A.

George

(2014). Are public–private partnerships a healthy option? A systematic literature review. Social Science & Medicine, 113, 110–119.

166.

Rosenberg

R. D.

(1987). Managerial morality and behavior: The questionable payments issue. Journal of Business Ethics, 6, 23–36.

167.

Russo

(2016). What is the CSR’s focus in healthcare? Journal of Business Ethics, 134, 323–334.

168.

Sachs

J. D.

Schmidt-Traub

Mazzucato

Messner

Nakicenovic

Rockström

(2019). Six Transformations to achieve the Sustainable Development Goals. Nature Sustainability, 2, 805–814.

169.

Schrempf

(2014). A social connection approach to corporate responsibility: The case of the fast-food industry and obesity. Business & Society, 53, 300–332.

170.

Scruggs

C. E.

Van Buren

H. J.

(2016). Why leading consumer product companies develop proactive chemical management strategies. Business & Society, 55, 635–675.

171.

Sen

(1999a). Economics and health. The Lancet, 354, Article SIV20.

172.

Sen

(1999b). Health in development. Bulletin of the World Health Organization, 77, 619–623.

173.

Sethi

Lowry

Veral

Shapiro

Emelianova

(2011). Freeport-McMoRan Copper & Gold, Inc.: An innovative voluntary code of conduct to protect human rights, create employment opportunities, and economic development of the indigenous people. Journal of Business Ethics, 103, 1–30.

174.

Shandra

C. L.

Shandra

J. M.

London

(2011). World Bank structural adjustment, water, and sanitation: A cross-national analysis of child mortality in Sub-Saharan Africa. Organization & Environment, 24(2), 107–129.

175.

Sidibe

(2020). Marketing meets mission. Harvard Business Review, 98(3), 134–144.

176.

Simola

(2010). Anti-corporate anger as a form of care-based moral agency. Journal of Business Ethics, 94, 255–269.

177.

Slawinski

Bansal

(2012). A matter of time: The temporal perspectives of organizational responses to climate change. Organization Studies, 33, 1537–1563.

178.

Small

(1973). Co-citation in the scientific literature: A new measure of the relationship between two documents. Journal of the American Society for Information Science, 24, 265–269.

179.

Stan

(2017). Healthy nutrition and health-washing corporate discourses across three organizations in the fast food and soft drinks industry. Journal of Comparative Research in Anthropology and Sociology, 8(1), 45–66.

180.

Staples

(2006). A new type of threat. Harvard Business Review, 84(5), 20–22.

181.

Strife

Downey

(2009). Childhood development and access to nature: A new direction for environmental inequality research. Organization & Environment, 22, 99–122.

182.

Stuckler

McKee

Ebrahim

Basu

(2012). Manufacturing epidemics: The role of global producers in increased consumption of unhealthy commodities including processed foods, alcohol, and tobacco. PLOS Medicine, 9(6), Article e1001235.

183.

Suchman

M. C.

(1995). Managing legitimacy: Strategic and institutional approaches. Academy of Management Review, 20, 571–610.

184.

Swinburn

B. A.

Kraak

V. I.

Allender

Atkins

V. J.

Baker

P. I.

Bogard

J. R.

Brinsden

Calvillo

De Schutter

Devarajan

Ezzati

Friel

Goenka

Hammond

R. A.

Hastings

Hawkes

Herrero

Hovmand

P. S.

Howden

. . .Dietz

W. H.

(2019). The global syndemic of obesity, undernutrition, and climate change: The Lancet Commission report. The Lancet, 393(10173), 791–846.

185.

Tansey

R. R.

Hyman

M. R.

(1995). Eradicating the pesticide problem in Latin America. Business and Society Review, 92, 55–59.

186.

Tebbens

R. J. D.

Thompson

K. M.

(2009). Priority shifting and the dynamics of managing eradicable infectious diseases. Management Science, 55, 650–663.

187.

Tempels

Blok

Verweij

(2020). Injustice in food-related public health problems: A matter of corporate responsibility. Business Ethics Quarterly, 30, 388–413.

188.

Thirumalai

Sinha

K. K.

(2011). Product recalls in the medical device industry: An empirical exploration of the sources and financial consequences. Management Science, 57, 376–392.

189.

Thompson

S. R.

Watson

M. C.

Tilford

(2018). The Ottawa Charter 30 years on: Still an important standard for health promotion. International Journal of Health Promotion and Education, 56(2), 73–84.

190.

Thorgren

Omorede

(2018). Passionate leaders in social entrepreneurship: Exploring an African context. Business & Society, 57, 481–524.

191.

Tosun

(2017). Polycentrism in global health governance scholarship. International Journal of Health Policy and Management, 7, 78–80.

192.

Tranfield

Denyer

Smart

(2003). Towards a methodology for developing evidence-informed management knowledge by means of systematic review. British Journal of Management, 14, 207–222.

193.

United Nations. (2015). Transforming our world: The 2030 agenda for Sustainable Development. https://sustainabledevelopment.un.org/post2015/transformingourworld

194.

United Nations. (2020). Goal 2: Zero hunger. https://un.org/sustainabledevelopment/hunger

195.

United Nations Development Programme. (2020). Goal 3: Good health and well-being. https://www.undp.org/content/oslo-governance-centre/en/home/sustainable-development-goals/goal-3-good-health-and-well-being.html

196.

Vakili

McGahan

A. M.

(2016). Health care’s grand challenge: Stimulating basic science on diseases that primarily afflict the poor. Academy of Management Journal, 59, 1917–1939.

197.

van Cranenburgh

K. C.

Arenas

. (2014). Strategic and moral dilemmas of corporate philanthropy in developing countries: Heineken in Sub-Saharan Africa. Journal of Business Ethics, 122, 523–536.

198.

van de Pol

P. K. C.

de Bakker

F. G. A.

(2010). Direct-to-consumer advertising of pharmaceuticals as a matter of corporate social responsibility? Journal of Business Ethics, 94, 211–224.

199.

Vogus

T. J.

Sutcliffe

K. M.

Weick

K. E.

(2010). Doing no harm: Enabling, enacting, and elaborating a culture of safety in health care. Academy of Management Perspectives, 24, 60–77.

200.

Walsh

(2018, June 8). Malady mongers: How drug companies sell treatments by inventing diseases. Huffington Post. https://www.huffpost.com/entry/malady-mongers-how-drug-companies-sell-treatments-by-inventing-diseases_n_5b1ab5e4e4b0adfb8268c762

201.

Watts

Amann

Arnell

Ayeb-Karlsson

Beagley

Belesova

Boykoff

Byass

Cai

Campbell-Lendrum

Capstick

Chambers

Coleman

Dalin

Daly

Dasandi

Dasgupta

Davies

Napoli

C. D.

. . .Costello

(2021). The 2020 report of The Lancet Countdown on health and climate change: Responding to converging crises. The Lancet, 397(10269), 129–170.

202.

Watts

Amann

Arnell

Ayeb-Karlsson

Belesova

Berry

Bouley

Boykoff

Byass

Cai

Campbell-Lendrum

Chambers

Daly

Dasandi

Davies

Depoux

Dominguez-Salas

Drummond

Ebi

K. L.

. . .Costello

(2018). The 2018 report of The Lancet Countdown on health and climate change: Shaping the health of nations for centuries to come. The Lancet, 392(10163), 2479–2514.

203.

Watts

Amann

Arnell

Ayeb-Karlsson

Belesova

Boykoff

Byass

Cai

Campbell-Lendrum

Capstick

Chambers

Dalin

Daly

Dasandi

Davies

Drummond

Dubrow

Ebi

K. L.

Eckelman

. . .Montgomery

(2019). The 2019 report of The Lancet Countdown on health and climate change: Ensuring that the health of a child born today is not defined by a changing climate. The Lancet, 394(10211), 1836–1878.

204.

Werhane

P. H.

Gorman

(2005). Intellectual property rights, moral imagination, and access to life-enhancing drugs. Business Ethics Quarterly, 15, 595–613.

205.

Wilkinson

R. G.

(2006). The impact of inequality. Social Research, 73, 711–732.

206.

Williamson

O. E.

(1985). The economic institutions of capitalism: Firms, markets, relational contracting. Free Press.

207.

Witty

(2011). New strategies for innovation in global health: A pharmaceutical industry perspective. Health Affairs, 30, 118–126.

208.

World Health Organization. (1946). Constitution of the World Health Organization. https://www.who.int/governance/eb/who_constitution_en.pdf

209.

World Health Organization. (1998). The WHO health promotion glossary. https://www.who.int/publications/i/item/WHO-HPR-HEP-98.1

210.

World Health Organization. (2018). Noncommunicable diseases. https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases

211.

World Health Organization. (2020). Communicable diseases. WHO Regional Office for Africa. https://www.afro.who.int/health-topics/communicable-diseases

212.

Wright

Nyberg

(2017). An inconvenient truth: How organizations translate climate change into business as usual. Academy of Management Journal, 60, 1633–1661.

213.

(2021). CEOs’ poverty experience and corporate social responsibility: Are CEOs who have experienced poverty more generous? Journal of Business Ethics. Advance online publication. https://doi.org/10.1007/s10551-021-04899-w

214.

Yach

Feldman

Z. A.

Bradley

D. G.

Khan

(2010). Can the food industry help tackle the growing global burden of undernutrition? American Journal of Public Health, 100, 974–980.

215.

Yani-de-Soriano

Javed

Yousafzai

(2012). Can an industry be socially responsible if its products harm consumers? The case of online gambling. Journal of Business Ethics, 110, 481–497.

216.

Young

O. R.

Berkhout

Gallopin

G. C.

Janssen

M. A.

Ostrom

van der Leeuw

(2006). The globalization of socio-ecological systems: An agenda for scientific research. Global Environmental Change, 16, 304–316.

217.

Ziady

(2021, August 9). One of the world’s biggest cigarette makers wants to buy an asthma inhaler company. CNN. https://www.cnn.com/2021/08/09/business/philip-morris-vectura/index.html

218.

Zwetsloot

Pot

(2004). The business value of health management. Journal of Business Ethics, 55, 115–124.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.07 MB

The Grand Challenge of Human Health: A Review and an Urgent Call for Business–Health Research

Abstract

Keywords

Get full access to this article

References

Supplementary Material